1. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study. Issue 11 (7th October 2016) Authors: Stallmach, A.; Langbein, C.; Atreya, R.; Bruns, T.; Dignass, A.; Ende, K.; Hampe, J.; Hartmann, F.; Neurath, M. F.; Maul, J.; Preiss, J. C.; Schmelz, R.; Siegmund, B.; Schulze, H.; Teich, N.; von Arnim, U.; Baumgart, D. C.; Schmidt, C. Journal: Alimentary pharmacology & therapeutics Issue: Volume 44:Issue 11/12(2016) Page Start: 1199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease – a prospective multicenter observational study. Issue 11 (7th October 2016) Authors: Stallmach, A.; Langbein, C.; Atreya, R.; Bruns, T.; Dignass, A.; Ende, K.; Hampe, J.; Hartmann, F.; Neurath, M. F.; Maul, J.; Preiss, J. C.; Schmelz, R.; Siegmund, B.; Schulze, H.; Teich, N.; von Arnim, U.; Baumgart, D. C.; Schmidt, C. Journal: Alimentary pharmacology & therapeutics Issue: Volume 44:Issue 11/12(2016) Page Start: 1199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗